Matinas BioPharma (MTNB)
NYSE MKT:MTNB
Holding MTNB?
Track your performance easily

Matinas BioPharma (MTNB) Income Statement

1,512 Followers

Matinas BioPharma Income Statement

Last quarter (Q2 2024), Matinas BioPharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Matinas BioPharma's net income was $-5.72M. See Matinas BioPharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-$ 1.10M$ 3.19M$ 33.00K$ 158.33K$ 89.81K
Cost of Revenue
------
Gross Profit
-$ 1.10M$ 3.19M$ 33.00K--
Operating Expense
$ 11.96M$ 24.86M$ 27.78M$ 24.77M$ 24.36M$ 19.01M
Operating Income
$ -23.76M$ -23.77M$ -24.59M$ -24.73M$ -24.21M$ -18.92M
Net Non Operating Interest Income Expense
-$ -3.00K$ -1.00K$ 3.00K--
Other Income Expense
$ -850.00K$ 824.00K$ -3.59M$ -1.45M$ 1.76M$ 1.55M
Pretax Income
$ -11.11M$ -22.94M$ -21.00M$ -23.28M$ -22.45M$ -17.37M
Tax Provision
-----$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -22.91M$ -22.94M$ -21.00M$ -23.68M$ -23.24M$ -18.30M
Basic EPS
$ -0.10$ -0.11$ -0.10$ -0.11$ -0.12$ -0.13
Diluted EPS
$ -0.10$ -0.11$ -0.10$ -0.11$ -0.12$ -0.13
Basic Average Shares
$ 901.24M$ 217.26M$ 216.81M$ 210.18M$ 196.89M$ 145.20M
Diluted Average Shares
$ 901.24M$ 217.26M$ 216.81M$ 210.18M$ 196.89M$ 145.20M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 11.96M$ 24.86M$ 27.78M$ 24.77M$ 24.36M$ 19.01M
Net Income From Continuing And Discontinued Operation
$ -22.91M$ -22.94M$ -21.00M$ -23.28M$ -22.45M$ -17.37M
Normalized Income
$ -14.64M$ -18.12M$ -16.59M-$ -23.52M$ -18.38M
Interest Expense
------
EBIT
$ -11.11M$ -22.94M$ -21.00M$ -23.29M$ -24.21M$ -18.92M
EBITDA
$ -10.13M$ -21.89M$ -19.89M$ -22.25M$ -23.43M$ -18.14M
Currency in USD

Matinas BioPharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis